To this end, the current goals of the study include: 1) Assess whether STMN2 loss of function is a feature of FTD, 2) generate a CRISPRi mouse model using Stmn2 depletion as a proof-of concept and 3) combine CRISPRi of Stmn2 with a C9ORF72 expanded repeat. Here, STMN2 is linked to frontotemporal dementia.